Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer Medicine|February 26, 2021
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapyMakoto Ueno, Chigusa Morizane, Masayuki Furukawa, et al.Cancer Science|June 14, 2022
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancerKensei Yamaguchi, Keiko Minashi, Daisuke Sakai, et al.Acta Medica Okayama|August 23, 2014
Prevalence and outcomes of acute hepatitis B in Okayama, Japan, 2006-2010Nozomu Wada, Tetsuya Yasunaka, Fusao Ikeda, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 1, 2022
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in JapanMasahiko Aoki, Shigenori Kadowaki, Naoki Takahashi, et al.Frontiers in Oncology|July 2, 2021
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil TreatmentHiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 13, 2017
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)Yuji Miura, Yasutaka Sukawa, Shuichi Hironaka, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 22, 2018
First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched studyAkitaka Makiyama, Kenji Kunieda, Masaaki Noguchi, et al.Journal of Gastroenterology|November 30, 2024
Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weightingHiroshi Imaoka, Masafumi Ikeda, Satoshi Kobayashi, et al.Journal of Gastroenterology|September 6, 2025
Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B)Satoshi Kobayashi, Kohei Nakachi, Kouji Yamamoto, et al.Cancers|February 13, 2025
BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS)Hiroya Taniguchi, Kay Uehara, Toshiaki Ishikawa, et al.Pageof 3